Ipilimumab vs Sars-Cov-2 Virus Spike Protein

## Ipilimumab vs Sars-Cov-2 Virus Spike Protein: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Sars-Cov-2 Virus Spike Protein**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Sars-Cov-2 Virus Spike Protein — N/A.

## Chemical Properties

**Type**: Ipilimumab — Antibody; Sars-Cov-2 Virus Spike Protein — Vaccine component.